Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.9800
At close: May 14 EDT
$0.9995
0.021.99%
Pre-Market: 5:54 PM EDT
Comments
Loading...
Acumen Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ABOS | Benzinga
Acumen Pharmaceuticals Inc has a consensus price target of $11.5 based on the ratings of 8 analysts. The high is $22 issued by BTIG on October 5, 2022. The low is $4 issued by UBS on March 28, 2025. The 3 most-recent analyst ratings were released by UBS, HC Wainwright & Co., and HC Wainwright & Co. on March 28, 2025, March 28, 2025, and November 13, 2024, respectively. With an average price target of $10 between UBS, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 900.50% upside for Acumen Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
HC Wainwright & Co.
Citigroup
Deutsche Bank
Credit Suisse
1calculated from analyst ratings
Analyst Ratings for Acumen Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | 300.2% | UBS | Colin Bristow38% | $6 → $4 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 1000.55% | HC Wainwright & Co. | Andrew Fein56% | $15 → $11 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 10/03/2024 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2024 | Buy Now | 500.3% | UBS | Colin Bristow38% | $14 → $6 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2024 | Buy Now | 600.35% | Citigroup | David Hoang41% | → $7 | Initiates | → Buy | Get Alert |
| 05/15/2024 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2024 | Buy Now | 1300.7% | UBS | Colin Bristow38% | $15 → $14 | Maintains | Buy | Get Alert |
| 03/27/2024 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 700.4% | Deutsche Bank | Neena Bitritto-Garg58% | → $8 | Initiates | → Buy | Get Alert |
| 08/09/2023 | Buy Now | 1200.65% | Credit Suisse | Judah Frommer65% | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/20/2023 | Buy Now | 1300.7% | B of A Securities | Geoff Meacham60% | → $14 | Reinstates | → Buy | Get Alert |
| 07/17/2023 | Buy Now | 1200.65% | Cantor Fitzgerald | Pete Stavropoulos41% | → $13 | Reiterates | Overweight → Overweight | Get Alert |
| 07/17/2023 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/18/2023 | Buy Now | 1200.65% | Cantor Fitzgerald | Pete Stavropoulos41% | → $13 | Initiates | → Overweight | Get Alert |
| 03/28/2023 | Buy Now | 1200.65% | Credit Suisse | Judah Frommer65% | $16 → $13 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | → Buy | Get Alert |
| 02/02/2023 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | → Buy | Get Alert |
| 11/15/2022 | Buy Now | 1500.8% | Credit Suisse | Judah Frommer65% | $17 → $16 | Maintains | Outperform | Get Alert |
| 10/05/2022 | Buy Now | 2101.1% | BTIG | Thomas Shrader39% | $15 → $22 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 1400.75% | BTIG | Thomas Shrader39% | → $15 | Initiates | → Buy | Get Alert |
| 06/30/2022 | Buy Now | 1400.75% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ:ABOS) was reported by UBS on March 28, 2025. The analyst firm set a price target for $4.00 expecting ABOS to rise to within 12 months (a possible 300.20% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ:ABOS) was provided by UBS, and Acumen Pharmaceuticals maintained their buy rating.
When was the last upgrade for Acumen Pharmaceuticals (ABOS)?
There is no last upgrade for Acumen Pharmaceuticals
When was the last downgrade for Acumen Pharmaceuticals (ABOS)?
There is no last downgrade for Acumen Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a maintained with a price target of $6.00 to $4.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $1.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
